CRP and interstitial lung disease: Although the primary (skin) endpoint was not met, both trials showed some efficacy and a good safety profile for using TCZ in SSc and evidenced a potential benefit of treating subclinical ILD patients with high risk features (early dcSSc, and elevated CRP) [50].